Open study in phase II to evaluate efficacy of initial R-CHOP [rituximab, cyclophosphamide, adriamycin, vincristine and prednisone] combination in folicular lymphoma no treated previously. Consolidation with one dose of 90Y ibritumomab tiuxetan (Zevalin) versus maintenance treatment with rituximab (MabThera)

Trial Profile

Open study in phase II to evaluate efficacy of initial R-CHOP [rituximab, cyclophosphamide, adriamycin, vincristine and prednisone] combination in folicular lymphoma no treated previously. Consolidation with one dose of 90Y ibritumomab tiuxetan (Zevalin) versus maintenance treatment with rituximab (MabThera)

Suspended
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Oct 2014 Status changed from recruiting to suspended due to no inclusion, as reported by ClinicalTrials.gov
    • 10 Dec 2013 Interim results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Mar 2012 Trial is to be expanded during 2012, according to a Spectrum Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top